The Pharmaceutical Research and Manufacturers of America (PhRMA) is launching a multi-million dollar ad campaign criticizing the 340B Drug Pricing Program, which provides discounted drugs to low-income patients. This matters as it highlights pharmaceutical lobbying efforts to influence federal drug pricing policies, potentially impacting how developers approach pricing strategies for new medications. The rising FDA rejection rate for cell and gene therapies also signals increased regulatory hurdles in these fields.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



